Redesigned lung cancer drug matches tumor control with fewer off-target interactions

Researchers at Moffitt Cancer Center have developed a new chemical approach to design targeted cancer medicines that are safer and more precise. The breakthrough allows drugs to bind more selectively to cancer-driving proteins while reducing unwanted interactions that cause side effects. This advancement in drug design could significantly improve treatment outcomes for lung cancer patients by maintaining tumor control while minimizing harmful off-target effects. The discovery represents an important step forward in personalized medicine, offering patients the potential for more effective therapies with improved tolerability and quality of life during cancer treatment.

Originally published on
Medical Xpress
Read full article(opens in new tab)Fetched: July 25, 2026 at 10:03 AM



